The clinical effectiveness agency for England and Wales says that it will most likely reject two chemotherapy treatments: vinflunine for the second-line treatment of urothelial tract cancer, and erlotinib for the maintenance treatment of non-small-cell lung cancer.The National Institute for Health and Clinical Effectiveness said in final draft guidance March 10 that it could not recommend vinflunine for the treatment of advanced or metastatic transitional cell carcinoma of the urothelial tract that...